Gilbert and Hemann’s study in lymphoma model described an interleukin 6 (IL-6)-triggered cytokine-chain response that can promote therapeutic resistance to genotoxic chemotherapy of lymphoma cells [10]. The gene discussed is IL6; the disease is lymphoma.